News
IMA
5.29
-10.49%
-0.62
ImageneBio, Inc. reports Q1 results
Seeking Alpha · 1d ago
Why Is Vanguard Total Stock Market (VTI) ETF Rising Today, 5/8/26?
TipRanks · 1d ago
ImageneBio price target lowered to $24 from $30 at Leerink
TipRanks · 2d ago
Analysts Offer Insights on Healthcare Companies: Guardant Health (GH), ImageneBio (IMA) and Natera (NTRA)
TipRanks · 2d ago
ImageneBio Q1 EPS $(0.95) Misses $(0.70) Estimate
Benzinga · 2d ago
Press Release: ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update
Dow Jones · 2d ago
Why Is Vanguard Total Stock Market (VTI) ETF Up Today, 5/7/26?
TipRanks · 2d ago
Why Is Vanguard Total Stock Market (VTI) ETF Rising Today, 5/6/26?
TipRanks · 3d ago
Why Is Vanguard Total Stock Market (VTI) ETF Rising Today, 5/5/26?
TipRanks · 4d ago
Why Is Vanguard Total Stock Market (VTI) ETF Down Today, 5/4/26?
TipRanks · 5d ago
Weekly Report: what happened at IMA last week (0427-0501)?
Weekly Report · 6d ago
Why Is Vanguard Total Stock Market (VTI) ETF Rising Today, 4/30/26?
TipRanks · 04/30 13:49
Why Is Vanguard Total Stock Market (VTI) ETF Down Today, 4/29/26?
TipRanks · 04/29 15:02
Why Is Vanguard Total Stock Market (VTI) ETF Down Today, 4/28/26?
TipRanks · 04/28 15:03
Why Is Vanguard Total Stock Market (VTI) ETF Down Today, 4/27/26?
TipRanks · 04/27 14:10
Weekly Report: what happened at IMA last week (0420-0424)?
Weekly Report · 04/27 10:25
Why Is Vanguard Total Stock Market (VTI) ETF Down Today, 4/23/26?
TipRanks · 04/23 14:23
Why Is Vanguard Total Stock Market (VTI) ETF Up Today, 4/22/26?
TipRanks · 04/22 14:19
Why Is Vanguard Total Stock Market (VTI) ETF  Up Today, 4/21/26?
TipRanks · 04/21 15:00
ImageneBio files Form 3 for Principal Accounting Officer Robert B. Lally
PUBT · 04/20 21:44
More
Webull provides a variety of real-time IMA stock news. You can receive the latest news about ImageneBio through multiple platforms. This information may help you make smarter investment decisions.
About IMA
ImageneBio, Inc., formerly Ikena Oncology, Inc., is a clinical-stage biotechnology company. The Company is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The Company develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The Company is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.